Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

CD79a: a novel marker for B-cell neoplasms in routinely processed tissue samples

D Y Mason1, J L Cordell, M H Brown

  • 1University Department of Cellular Science, John Radcliffe Hospital, Oxford, UK.

Blood
|August 15, 1995
PubMed
Summary

A new anti-CD79a antibody, JCB117, effectively identifies B-cell neoplasms in paraffin-embedded tissues. This reliable marker aids in diagnosing B-cell malignancies across all maturation stages, including precursor B-cell acute lymphoblastic leukemia.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The Value of Immunocytochemistry in Differentiating High-Grade: Lymphoma from Other Anaplastic Tumours: A study of anaplastic tumours from 1940 to 1960.

Leukemia & lymphoma·2016
Same author

Immunocytochemical Analysis of Lymphoid Lesions Using -Fine Needle Aspiration Biopsy.

Leukemia & lymphoma·2016
Same author

Plasma Amino Acids in Children under Two Years of Age with Severe Undernutrition. Increase of Taurine in Kwashiorkor.

Nutritional neuroscience·2016
Same author

The occupational therapist as a consultant.

Occupational therapy in health care·2013
Same author

From the editor's desk.

Occupational therapy in health care·2013
Same author

Medical consumer education.

Occupational therapy in health care·2013

Area of Science:

  • Immunology
  • Oncology
  • Histopathology

Background:

  • The CD79 molecule (CD79a/CD79b) is crucial for B-cell receptor signaling.
  • CD79a is present from early B-cell development through plasma cells.

Purpose of the Study:

  • To evaluate a novel anti-CD79a monoclonal antibody, JCB117, for B-cell identification in formalin-fixed, paraffin-embedded tissues.
  • To assess the utility of JCB117 in diagnosing B-cell neoplasms.

Main Methods:

  • Testing of the JCB117 antibody on 454 paraffin-embedded tissue biopsies.
  • Analysis of reactivity across various B-cell maturation stages and non-B-cell neoplasms.

Main Results:

  • JCB117 reacted with 97% of B-cell neoplasms, including myeloma/plasmacytoma.

Related Experiment Videos

  • The antibody successfully labeled precursor B-cell acute lymphoblastic leukemia.
  • All T-cell and non-lymphoid neoplasms tested were negative for JCB117.

    • Conclusions:

    • JCB117 is a highly sensitive and specific marker for B-cell neoplasms in paraffin-embedded sections.
    • This antibody is valuable for histopathological diagnosis of B-cell malignancies.
    • JCB117 offers reliable detection of B-cell markers in challenging specimens like bone marrow trephines.